INmune Bio Inc. - Common stock (INMB): Price and Financial Metrics

INmune Bio Inc. - Common stock (INMB)

Today's Latest Price: $20.48 USD

0.24 (-1.16%)

Updated Jan 25 6:55pm

Add INMB to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

INMB Stock Price Chart Interactive Chart >

Price chart for INMB

INMB Price/Volume Stats

Current price $20.48 52-week high $29.99
Prev. close $20.72 52-week low $2.20
Day low $20.01 Volume 461,500
Day high $22.47 Avg. volume 508,807
50-day MA $13.41 Dividend yield N/A
200-day MA $9.37 Market Cap 275.42M

INmune Bio Inc. - Common stock (INMB) Company Bio

INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.

INMB Latest News Stream

Event/Time News Detail
Loading, please wait...

INMB Latest Social Stream

Loading social stream, please wait...

View Full INMB Social Stream

Latest INMB News From Around the Web

Below are the latest news stories about Inmune Bio Inc that investors may wish to consider to help them evaluate INMB as an investment opportunity.

Why INmune Bio Stock Soared Then Sank Today

INmune's shares were sinking 17% as of 3:39 p.m. EST. The big jump came after the biotech announced encouraging results from a phase 1b study evaluating XPro1595 in treating Alzheimer's disease. It's not all that surprising to see such high volatility for a clinical-stage biotech stock.

Yahoo | January 21, 2021

The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20) * 10X Genomics Inc (NASDAQ: TXG) * ABIOMED, Inc. (NASDAQ: ABMD) * Aclaris Therapeutics Inc (NASDAQ: ACRS) * Adamis Pharmaceuticals Corp(NASDAQ: ADMP) (announced IND submission of Tempol for COVID-19 treatment) * Akari Therapeutics PLC (NASDAQ: AKTX) * Aligos Therapeutics Inc (NASDAQ: ALGS) * Alimera Sciences Inc (NASDAQ: ALIM) * Atea Pharmaceuticals Inc (NASDAQ: AVIR) * Beigene Ltd (NASDAQ: BGNE) * Bicycle Therapeutics PLC (NASDAQ: BCYC) * BIO-TECHNE Corp (NASDAQ: TECH) * BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) * Biodesix Inc (NASDAQ: BDSX) * BioVie Inc (NASDAQ: BIVI) * Caladrius Biosciences Inc (NASDAQ: CLBS) * Cara Ther...

Yahoo | January 21, 2021

INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial

Interim data show CSF biomarkers of neurodegeneration and synaptic dysfunction as well as neuroimaging biomarkers improved after three months of therapy with XPro1595 Data support initiation of blinded randomized Phase 2 study before year end Company to host Key Opinion Leader Webinar Today, January 21, at 8:00am ET LA JOLLA, Calif, Jan. 21, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that results from a Phase 1b study demonstrate that XPro1595, an investigational dominant-negative protein that neutralizes soluble TNF, decreases biomarkers of neuroinflammation across multiple measures and assays, including ce...

Yahoo | January 21, 2021

INmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ET

Webinar to review expanded biomarker data from the company’s Phase 1b clinical trial of XPro1595 targeting neuroinflammation in patients with Alzheimer’s diseaseLA JOLLA, Calif, Jan. 13, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the company will host a Key Opinion Leader (KOL) webinar on Thursday, January 21, from 8:00 AM – 9:00 AM Eastern Time. The webinar will present new biomarker data from the company’s Phase 1b trial of its lead clinical candidate, XPro1595, in patients with Alzheimer’s disease (AD) and biomarkers of inflammation. The primary goal of this 12 week trial is to demonstrate that XPro...

Yahoo | January 13, 2021

Do Hedge Funds Love Inmune Bio Inc. (INMB)?

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

Yahoo | November 27, 2020

Read More 'INMB' Stories Here

INMB Price Returns

1-mo N/A
3-mo 162.56%
6-mo 74.30%
1-year 324.90%
3-year N/A
5-year N/A
YTD 18.93%
2020 196.90%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6834 seconds.